Fresenius Kabi's tocilizumab biosimilar Tyenne® is the first and only tocilizumab biosimilar to be launched in Canada and is ...

Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and Formycon AG, an independent developer of biosimilars ...

Formycon und Fresenius Kabi geben Markteinführung des Ustekinumab-Biosimilars FYB202/Otulfi (TM) in Kanada bekannt ^ EQS-News ...

Director and Head of Commercial, Fresenius Kabi Biopharma, Canada. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important ...

Fresenius SE FRE0.00%increase; green up pointing triangle raised its full-year guidance after a strong third quarter driven by Kabi and good organic growth at Helios. The German healthcare company ...

With this approval, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Otulfi TM is ...

The company carries the values, mission and vision of its mother global healthcare company based in Germany, Fresenius Kabi Deutschland GmbH. For more stories of how Fresenius Kabi has taken care ...

The agreement resolves a patent litigation between the company and Fresenius Kabi, Jiangsu Hengrui Pharmaceuticals, and eVenus Pharmaceuticals Laboratories regarding Pacira’s (NASDAQ:PCRX ...

Fresenius Kabi's plant on Grand Island has a slogan: Saving lives one vial at a time. The plant, which employs about 800 people, makes sterile, injectable pharmaceuticals, used in doctors' offices ...

EQS-News: Formycon und Fresenius Kabi geben Markteinführung des Ustekinumab-Biosimilars FYB202/Otulfi™ in Kanada bekannt ...

Fresenius Kabi's ustekinumab biosimilar Otulfi ™ is now commercially available for both subcutaneous and intravenous formulations With this launch, Fresenius Kabi Canada's immunology biosimilar ...

TORONTO, May 27, 2025 /CNW/ - Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi ™ is indicated for the ...